FDA Approves Voxelotor for Sickle Cell Disease
Nov 26
2019
The Food and Drug Administration granted accelerated approval to voxelotor (Oxbryta, Global Blood Therapeutics) for adults and pediatric patients 12 years of age and older with sickle cell disease.